Spartalizumab Biosimilar, Human PD-1 Monoclonal Antibody
Specificité
The in vivo grade spartalizumab biosimilar specifically binds to the programmed cell death protein 1 (PD-1), antagonizing its interaction with its known ligands PD-L1 and PD-L2.
Attributs du produit
Recombinant Humanized IgG4 Monoclonal Antibody.
Purification
Protein A affinity column
Pureté
> 95% by SDS-PAGE under reducing conditions and HPLC.
Stérilité
0.2 μm filtered
niveau d'endotoxine
< 1 EU per 1 mg of the protein by the LAL method.
Immunogène
The anti-human PD-1 monoclonal antibody spartalizumab biosimilar was produced in mammalian cells.
Isotype
IgG4 kappa
Indications d'application
ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by spartalizumab.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
PBS, pH 7.4, no stabilizers or preservatives.
Agent conservateur
Without preservative
Conseil sur la manipulation
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Stock
-20 °C
Stockage commentaire
12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Date de péremption
12 months
Antigène
PDCD1 (Spartalizumab Biosimilar)
Classe de substances
Biosimilar
Sujet
Spartalizumab Biosimilar uses the same protein sequences as the therapeutic antibody spartalizumab. A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.